January 24th 2024
Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.
February 14th 2022
Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.
February 7th 2022
Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.
January 31st 2022
Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.
January 22nd 2021
January 18th 2021
December 23rd 2020